Orange Book product · Brand (NDA)
OLPRUVA
SODIUM PHENYLBUTYRATE
At a glance
Dec 22, 2022
Approved
Brand (NDA)
Application
Not listed
TE code
3
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Dec 22, 2022
3 yr 7 mo ago
Today
Patent 11154521 expires
Listed drug product patent expiration.
Oct 17, 2036
in 10 yr 6 mo
Patent 11202767 expires
Listed method-of-use patent (U-3502) expiration.
Oct 17, 2036
in 10 yr 6 mo
Patent 11433041 expires
Listed drug product patent expiration.
Oct 17, 2036
in 10 yr 6 mo
Pharmaceutical detail
Active ingredient
SODIUM PHENYLBUTYRATE
Strength
5GM/PACKET
Dosage form
FOR SUSPENSION
Route
ORAL
TE code
Not listed
Application
NDA 214860
Product number
004
Marketing status
RX
Reference listed drug (RLD)
Yes
Reference standard (RS)
Yes
Active-ingredient family
View full familyThis is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.
- 2022PHEBURANEBrand (NDA)
NDA 216513 · MEDUNIK
- 1996BUPHENYLBrand (NDA)
NDA 020572 · HORIZON THERAP US
- 1996BUPHENYLBrand (NDA)
NDA 020573 · HORIZON THERAP US
- 2026SODIUM PHENYLBUTYRATEGeneric (ANDA)
ANDA 220418 · NAVINTA LLC
- 2022SODIUM PHENYLBUTYRATEGeneric (ANDA)
ANDA 216462 · GLENMARK PHARMS LTD
- 2016SODIUM PHENYLBUTYRATEGeneric (ANDA)
ANDA 203918 · PH HEALTH
- 2016SODIUM PHENYLBUTYRATEGeneric (ANDA)
ANDA 204395 · PH HEALTH
- 2013SODIUM PHENYLBUTYRATEGeneric (ANDA)
ANDA 202819 · SIGMAPHARM LABS LLC
- 2011SODIUM PHENYLBUTYRATEGeneric (ANDA)
ANDA 090910 · ALVOGEN
Listed patents (3)
| Patent | Expires | In | Type |
|---|---|---|---|
| 11154521 | Oct 17, 2036 | in 10 yr 6 mo | Product |
| 11202767 | Oct 17, 2036 | in 10 yr 6 mo | U-3502 |
| 11433041 | Oct 17, 2036 | in 10 yr 6 mo | Product |

